Saudi Chemical Company Holding Announces Signing Exclusive Agreement by Its Subsidiary AJA Pharma with Bioventure for the Drug “Ruxolitinib”
|Announcement Detail||Saudi Chemical Company Holding (SCCH), through its pharmaceutical sector represented by AJA Pharmaceutical Industries Ltd. (AJA Pharma), announces signing an exclusive agreement with Bioventure FZ-LLC, a subsidiary of GlobalOne Healthcare Holding (GHH) on Tuesday, 09\07\1444H corresponding to, 31\01\2023 , in the Saudi Export stand during Arab Health Exhibition 2023, where AJA Pharma will get exclusive licensing rights for the drug “Ruxolitinib”. which is a type of cancer drug, used to treat some types of neoplasms. |
Under this agreement, AJA Pharma will have exclusive commercialization rights of Ruxolitinib in the Kingdom of Saudi Arabia, the rest of the GCC, and Levant countries. AJA Pharma will also have rights to the transfer of technology in the future for the manufacturing of the drug in Saudi Arabia.
By this agreement, AJA Pharma aims at strengthening its position in Saudi and Global markets in the field of Oncology, Diabetes and Specialty products, to serve and meet community needs in line with Saudi Vision’s objectives 2030 to localize value-added specialty drugs
The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.
Last Price 28.9
Net Change -0.1 (-0.34%)
Value Traded (Sar) 2,660,952.45
Volume Traded 91,843
Log in to access your watchlist
Don't Have Account? Register Here